Saturday 17 October 2026
Export MDRX’s income statement to Excel — free account
Veradigm Inc.
MDRX Healthcare Health Information Services
5.00
0.00
0.00%
Follow MDRX
| Dec '22 | Sep '22 | Jun '22 | Mar '22 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 30.46 | 29.66 | 18.46 |
+8 more quarters Free account |
P/S ratio |
3.28 | 2.78 | 2.84 | 4.45 | |
P/FCF ratio |
22.83 | 14.25 | 11.85 | 0.00 | |
P/Operating CF |
91.66 | 59.64 | (1,036.29) | 37.67 | |
P/B ratio |
1.90 | 1.43 | 1.42 | 1.93 | |
Price to Tangible BV |
4.88 | 3.31 | 3.24 | 3.87 | |
EV/Sales |
2.94 | 2.38 | 2.42 | 5.03 | |
EV/EBITDA |
22.08 | 11.38 | 11.84 | 20.18 | |
EV/Operating CF |
14.82 | 8.98 | 7.69 | (247.32) | |
EV/FCF |
20.47 | 12.17 | 10.07 | (53.76) | |
Quick Ratio |
2.46 | 2.62 | 2.61 | 0.39 | |
Current Ratio |
2.95 | 3.20 | 3.23 | 2.38 | |
Net Debt/EBITDA |
(25.06) | (7.56) | (33.48) | 14.17 | |
Debt/Assets |
13.32% | 11.85% | 11.66% | 15.52% | |
Debt/Equity |
0.20 | 0.17 | 0.17 | 0.28 | |
Asset Turnover |
0.31 | 0.29 | 0.28 | 0.22 | |
Operating CF/Net income |
(0.35) | 1.94 | 0.03 | 3.03 | |
Capex/Depreciation |
(0.07) | (0.59) | (0.69) | (0.71) | |
Interest Coverage |
(49.14) | 20.07 | (2.84) | 3.08 | |
Research and Development Expense of Revenue |
19.67% | 15.59% | 15.08% | 16.42% | |
Selling, General and Administrative Expense of Revenue |
24.92% | 21.40% | 39.66% | 28.96% | |
Intangible Assets out of Total Assets |
0.41 | 0.40 | 0.39 | 0.28 | |
Share Based Compensation of Revenue |
3.66% | 3.00% | 5.98% | 4.43% | |
Graham Net Nets |
0.10 | 0.18 | 0.18 | 0.18 | |
Graham Number |
0.00 | 10.96 | 10.85 | 17.90 | |
Earnings Yield |
(4.47%) | 3.28% | 3.37% | 5.42% | |
Free Cash Flow Yield |
4.38% | 7.02% | 8.44% | (2.10%) | |
Revenue per Share |
1.27 | 1.38 | 1.32 | 1.23 | |
Operating CF per Share |
0.19 | 0.26 | (0.01) | 0.60 | |
Capex per Share |
(0.04) | (0.07) | (0.09) | (0.09) | |
Free Cash Flow per Share |
0.15 | 0.18 | (0.10) | 0.51 | |
Cash per Share |
4.00 | 4.48 | 4.39 | 0.73 | |
Shareholders Equity per Share |
9.08 | 10.68 | 10.47 | 11.68 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
9.08 | 10.68 | 10.47 | 11.68 | |
Free Cash Flow |
16.87 | 19.97 | (11.60) | 59.32 | |
Working Capital |
449.34 | 557.68 | 572.44 | 893.83 | |
Capital Expenditures |
(4.18) | (8.17) | (9.96) | (9.94) | |
Net Current Asset Value |
192.43 | 297.13 | 310.90 | 463.54 | |
EV/EBIT |
0.00 | 23.90 | 26.97 | 39.02 | |
Capex to Sales |
0.03 | 0.05 | 0.07 | 0.07 | |
Price to Operating Income |
0.00 | 28.00 | 31.71 | 34.51 | |
| Other line items | |||||
Average Receivables |
119.42 | 254.98 | 252.67 | 277.49 | |
Average Payables |
16.51 | 17.21 | 22.40 | 21.22 | |
Average Assets |
1,907.87 | 2,087.48 | 2,127.26 | 2,650.82 | |
Average Common Equity |
1,188.94 | 1,297.81 | 1,294.91 | 1,515.88 |
Columns are period end dates · fundamentals updated 1 Oct 2026